GHP Specialty Care AB (GHP) (STO:GHP), a health care provider that operates specialist clinics in a select number of diagnostic areas, reported on Friday result after tax of SEK11.5m, or result per share of SEK0.13, for the second quarter of 2020.
This was a decline over result after tax of SEK12.7m, or result per share of SEK0.17, in Q2 2019.
Sales revenues for the quarter amounted to SEK317.0m, as compared with SEK335.7m in Q2 2019. Organic growth was a negative 8.2%.
According to GHP, revenues decreased in the quarter due to Covid-19 pandemic effects.
As a health care Group, GHP has had to manage the consequences of the COVID-19 pandemic at close quarters. In the Nordic Region it has lent personnel, material and equipment to the public hospitals, at the same time as it had to cancel the appointments of all risk-group patients.
Internationally, GHP adapted to taking care of almost only COVID-19 patients in the UAE, and in Kuwait the hospital is now temporarily a paediatric hospital.
(EUR1.00=SEK10.39)
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development